Levagen+® (PEA) and HydroCurc® are two of the most clinically researched ingredients in modern nutritional science. Across both ingredients, there are now 22 published human clinical trials exploring areas including joint health, sleep quality, recovery, cognition, immune health, skin health, and inflammatory balance.
Importantly, the majority of these studies are randomised, double-blind, placebo-controlled trials — the gold standard in clinical research. Where relevant, we’ve highlighted studies that use dosages aligned with the recommended directions for Daily Vitals.
Levagen+® (PEA) Clinical Research Summary
16 Human Clinical Studies
Levagen+® is a highly bioavailable form of palmitoylethanolamide (PEA), extensively studied for its role in comfort, recovery, sleep, nervous system balance, and stress resilience.
Joint Health & Comfort
2019 – Knee Osteoarthritis Study
Dose: 300–600 mg/day for 8 weeks
Results: Significant reductions in WOMAC score, improved joint pain, stiffness and function, reduced anxiety
2021 – Joint Discomfort Study
Dose: 350 mg/day for 8 weeks
Results: Reduced joint discomfort in as little as 3 days, improved quality of life
Absorption & Bioavailability
2020 – Pharmacokinetic Study
Dose: 300 mg single dose
Results: Significant increase in plasma PEA concentration; 1.75× higher absorption vs standard PEA
Exercise Recovery & Performance
2020 – Exercise Recovery Study
Dose: 167.5 mg single dose
Results: Reduced muscle damage markers, faster recovery, lower blood lactate, enhanced muscle adaptation
2024 – Skeletal Muscle Hypertrophy Study
Dose: 300 mg/day for 8 weeks
Results: Increased lower-body power output and explosive force production
Sleep, Mood & Immune Health
2021 – Sleep Study
Dose: 350 mg/day for 8 weeks
Results: Improved sleep latency, morning alertness, cognitive performance; no next-day drowsiness
2021 – URTI / Immune Study
Dose: 350 mg/day for 2 weeks
Results: Reduced cold symptoms, scratchy throat and cough severity
Neurological & Inflammatory Support
2022 – Peripheral Neuropathic Discomfort Study
Dose: 600 mg/day for 8 weeks
Results: Reduced neuropathic discomfort, lower inflammatory cytokines, improved sleep and mood
2022 – Headache Study (vs Ibuprofen)
Dose: 525 mg Levagen+® vs 400 mg ibuprofen
Results: Comparable headache pain reduction; faster relief in some participants
2022 – COVID-Related Inflammation Study
Dose: 600 mg twice daily for 4 weeks
Results: Reduced pro-inflammatory cytokines (IL-1β, IL-2), lower sP-selectin
Cognitive & Stress Resilience
2024 – Cognitive Function Study
Dose: 700 mg/day for 6 weeks
Results: Increased BDNF, improved memory, fewer task errors
2025 – Stress & HRV Study
Dose: 600 mg/day for 6 weeks
Results: Improved HRV and reduced perceived stress
Emerging & Specialised Research
2023 – Seasonal Allergy Study (350 mg/day, 2 weeks): Reduced histamine markers and allergy symptoms
2024 – Migraine Study (600 mg single dose): Reduced pain severity and rescue medication use
2024 – Eczema Study (Topical): Reduced redness, dryness, itching; improved POEM scores
2025 – Menstrual Pain Study (300 mg at pain onset): Reduced pain scores within 1–2.5 hours post-dose
HydroCurc® Clinical Research Summary
6 Human Clinical Studies
HydroCurc® is a highly bioavailable curcumin extract designed to overcome the absorption challenges of standard curcumin.
Bioavailability & Absorption
2018 – Pharmacokinetic Study
Dose: 500 mg single dose
Results: Achieved 807 ng/mL plasma concentration — over 3× higher absorption than standard curcumin
Exercise Recovery & Inflammation
2020 – Exercise Recovery Study
Dose: 500 mg pre- and post-exercise
Results: Reduced DOMS, swelling, and lactate accumulation; faster recovery
2022 – Antioxidant & Inflammatory Balance Study
Dose: 500 mg/day for 6 weeks
Results: Improved inflammatory balance and reduced oxidative stress markers (TBARS)
Cognitive Health & Iron Compatibility
2020 – Cognitive Function / BDNF Study
Dose: 500 mg HydroCurc® + 18 mg iron for 6 weeks
Results: Increased BDNF, improved cognitive performance and task accuracy
2018 & 2021 – Iron Absorption Studies
Dose: 500 mg HydroCurc® + 18 mg iron
Results: Demonstrated compatibility with iron supplementation
Why This Research Matters
Together, Levagen+® and HydroCurc® represent a science-led approach to healthspan support, with clinically validated benefits across mobility, recovery, cognition, sleep, immune health, and inflammatory balance.
These ingredients aren’t supported by theory alone — they are backed by robust human clinical research, using dosages relevant to real-world supplementation.
